HCB303
Asset
Trispecific immunotherapy targeting PD-L1 and CD47 while intercepting TIGIT ligands
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- CD47
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Advanced solid tumor
Phase 1, prnewswire.com, 5 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets3
- Competitors7
Every asset’s record: target, stage, trials and the evidence behind it.